Personalis

Personalis Enterprise Value

The Enterprise Value (EV) of Personalis (PSNL) as of Oct 15, 2026 is 497.21 M USD. In the previous year, Enterprise Value (EV) was 545.85 M USD — a change of -8.91% (lower).

Enterprise Value

497.21 MUSD

YoY

-8.91%

Last updated:

Enterprise Value (EV) of Personalis is 2025 497.21 M USD. Enterprise Value (EV) of Personalis was 2024 545.85 M USD. It decreases by -8.91% lower compared to the previous year.

The Personalis Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
715.04 M USD
Jan 1, 2019
600.79 M USD
Jan 1, 2020
525.79 M USD
Jan 1, 2021
445.52 M USD
Jan 1, 2022
564.03 M USD
Jan 1, 2023
617.78 M USD
Jan 1, 2024
545.85 M USD
Jan 1, 2025
497.21 M USD
The Personalis Enterprise Value history
YEAREnterprise ValueYoY
497.21 MUSD-8.91%
545.85 MUSD-11.64%
617.78 MUSD+9.53%
564.03 MUSD+26.60%
445.52 MUSD-15.27%
525.79 MUSD-12.48%
600.79 MUSD-15.98%
715.04 MUSD-1.27%
724.27 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

Enterprise Value (EV) of Personalis is 497.21 M USD in 2025.

Enterprise Value (EV) of Personalis changed from 545.85 M USD to 497.21 M USD, representing a -8.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Personalis since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Personalis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Personalis

All Key Metrics — Personalis